Table 2.
Paper | Type of GI toxicity | Age/sex | Tumour | Oncological treatment | Symptoms | Upper GI endoscopic findings | Upper GI histology | Lower GI endoscopic findings | Lower GI histology | Treatment |
---|---|---|---|---|---|---|---|---|---|---|
Mohamed et al.26 | Ileal perforation | 52 F |
Vulval melanoma | Ipilimumab/nivolumab | Abdominal pain; nausea; weight loss | Not performed | Not performed | Ileal perforation on laparotomy | Transmural ischaemic necrosis | Systemic steroids; infliximab; resection of terminal ileum |
Smith et al.27 | Ileitis | 44 F |
Melanoma | Ipilimumab/nivolumab | Diarrhoea | Not performed | Not performed | Microerosions of terminal ileum; normal colon | Ileum; increased eosinophils; villous congestion | Systemic steroids |
Sokal et al.28 | Diffuse enteritisa | 48 F |
Melanoma | Ipilimumab/nivolumab | Diarrhoea; fever; vomiting; weight loss | Normal | Non-specific acute duodenitis | Erythematous right colon; normal terminal ileum | Non-specific oedema on colonic and ileal biopsies | Systemic steroids |
Sanders et al.29 | Gastritis and terminal ileitis | 43 M |
Melanoma | Ipilimumab/nivolumab | Diarrhoea; nausea; vomiting; weight loss | Gastric erythema and spontaneous oozing of blood | Gastritis; duodenal inflammation | Ileal aphthous ulcers; normal colon mucosa | Ileal lamina propria lymphoplasmacytosis with eosinophilic infiltration | Systemic steroids; infliximab |
Yang et al.30 | Eosinophilic enteritis | 68 M |
Melanoma | Pembrolizumab, talimogene, laherparepvec, ipilimumab/nivolumab | Diarrhoea; abdominal pain; nausea; skin rash; cough | Normal | Marked eosinophilia (80–100/HPF) on duodenal biopsies | Not performed | Not performed | Systemic steroids |
Young et al.31 | Enteritis and small bowel bleeding | 71 M |
Colon adenocarcinoma | Atezolizumab | Diarrhoea; abdominal pain; massive GI bleeding | Multiple duodenal and jejunal ulcers on enteroscopy | Non-specific abnormalities | Normal | Normal | Systemic steroids; infliximab; jejunal resection |
Otagiri et al.32 | Enteritis | 68 M |
Pleural mesothelioma | Nivolumab | Diarrhoea; abdominal pain; melena; fever | Gastric and small bowel aphthous ulcers on OGD and CE | Not reported | Diffuse aphthous ulcers on colonoscopy | Not reported | Systemic steroids |
Saito et al.33 | Acute duodenal haemorrhage | 66 M |
Small-cell lung cancer | Carboplatin + etoposide + atezolizumab | Haematemesis; diarrhoea | Large duodenal ulcers with pulsatile bleeding | Duodenal lymphocyte, eosinophil and plasma cell infiltrate | Normal | Not reported | Endoscopic haemostasis; supportive therapy |
Trystram et al.34 | Diffuse ulcerative haemorrhagic enteritis | 62 M |
Melanoma | Ipilimumab/nivolumab | Fever; melena; haemorrhagic shock | Normal | Not reported | Multiple deep bleeding jejunal and ileal ulcers; ulcerated Meckel diverticulum | Non-specific ileitis | Systemic steroids; antibiotics; Meckel diverticulum resection; infliximab |
Abdominal CT scan revealed diffuse small bowel wall thickening with contrast enhancement.
CE, capsule endoscopy; F, female; GI, gastrointestinal; HPF, high-power field; M, male; OGD, oesophagogastroduodenoscopy.